Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis to acquire Takeda's dry eye treatment Xiidra in a deal valued at up to $5.3 billion

firstwordpharmaMay 09, 2019

Tag: Novartis , Takeda , Xiidra

PharmaSources Customer Service